Genomic Health, Inc. (NASDAQ:GHDX) is scheduled to release its earnings data after the market closes on Monday, October 30th. Analysts expect Genomic Health to post earnings of $0.01 per share for the quarter.
Genomic Health (NASDAQ:GHDX) last released its quarterly earnings data on Tuesday, August 1st. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.06) by ($0.02). Genomic Health had a negative net margin of 1.50% and a negative return on equity of 4.33%. The company had revenue of $85.50 million for the quarter, compared to analyst estimates of $86.08 million. During the same quarter in the prior year, the firm earned ($0.18) EPS. The company’s revenue for the quarter was up 4.3% compared to the same quarter last year. On average, analysts expect Genomic Health to post $-0.04 EPS for the current fiscal year and $0.36 EPS for the next fiscal year.
Genomic Health, Inc. (NASDAQ GHDX) opened at 33.62 on Friday. The company’s 50-day moving average price is $32.08 and its 200-day moving average price is $31.77. The firm’s market cap is $1.16 billion. Genomic Health, Inc. has a 52-week low of $26.37 and a 52-week high of $34.02.
ILLEGAL ACTIVITY WARNING: This piece of content was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2017/10/28/genomic-health-inc-ghdx-scheduled-to-post-earnings-on-monday.html.
Several equities research analysts have recently weighed in on the company. Canaccord Genuity reiterated a “buy” rating and issued a $35.00 price objective on shares of Genomic Health in a research note on Wednesday, September 27th. BidaskClub lowered Genomic Health from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. Piper Jaffray Companies reiterated a “hold” rating and issued a $31.00 price objective on shares of Genomic Health in a research note on Thursday, August 3rd. Jefferies Group LLC reiterated a “hold” rating and issued a $34.00 price objective on shares of Genomic Health in a research note on Friday, October 20th. Finally, Zacks Investment Research lowered Genomic Health from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. One analyst has rated the stock with a sell rating, seven have issued a hold rating and one has issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $32.00.
In related news, insider Kimberly J. Popovits sold 5,000 shares of the stock in a transaction that occurred on Monday, August 14th. The stock was sold at an average price of $30.22, for a total transaction of $151,100.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider James J. Vaughn sold 8,000 shares of the stock in a transaction that occurred on Tuesday, August 8th. The stock was sold at an average price of $30.59, for a total value of $244,720.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 33,000 shares of company stock worth $1,022,620. Corporate insiders own 46.20% of the company’s stock.
Genomic Health Company Profile
Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.
Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.